U.S. Markets close in 2 hrs 25 mins
  • S&P 500

    4,292.76
    +12.61 (+0.29%)
     
  • Dow 30

    33,905.50
    +144.45 (+0.43%)
     
  • Nasdaq

    13,105.61
    +58.42 (+0.45%)
     
  • Russell 2000

    2,014.92
    -1.70 (-0.08%)
     
  • Crude Oil

    89.04
    -3.05 (-3.31%)
     
  • Gold

    1,797.40
    -18.10 (-1.00%)
     
  • Silver

    20.27
    -0.43 (-2.07%)
     
  • EUR/USD

    1.0171
    -0.0087 (-0.8442%)
     
  • 10-Yr Bond

    2.7820
    -0.0670 (-2.35%)
     
  • Vix

    19.98
    +0.45 (+2.30%)
     
  • GBP/USD

    1.2072
    -0.0066 (-0.5457%)
     
  • USD/JPY

    133.2280
    -0.2520 (-0.1888%)
     
  • BTC-USD

    24,190.39
    -89.72 (-0.37%)
     
  • CMC Crypto 200

    575.59
    -15.17 (-2.57%)
     
  • FTSE 100

    7,509.15
    +8.26 (+0.11%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

Recap: Inspire Medical Systems Q3 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Inspire Medical Systems (NYSE:INSP) rose 9.53% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 14.71% over the past year to ($0.39), which beat the estimate of ($0.72).

Revenue of $35,842,000 higher by 71.81% from the same period last year, which beat the estimate of $22,750,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $110,000,000 and $112,000,000.

Details Of The Call

Date: Nov 02, 2020

View more earnings on INSP

Time: 05:00 PM

ET Webcast URL: http://public.viavid.com/player/index.php?id=141564

Price Action

Company's 52-week high was at $135.20

Company's 52-week low was at $40.53

Price action over last quarter: Up 11.81%

Company Profile

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.